Navigation Links
VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
Date:2/11/2008

S-4, and a related proxy statement/prospectus, in connection with the merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus because they will contain important information about the merger transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting VaxGen Investor Relations at the email address: ir@vaxgen.com.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

VaxGen, Raven and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of VaxGen in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of VaxGen is also included in VaxGen's definitive proxy statement for its 2007 Annual Meeting of Stockholders which was filed with the SEC on November 21, 2007 and its Annual Report on Form 10-K for the year ended December 31, 2006, which was filed with the SEC on August 30, 2007.
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
10. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
11. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... that it will hold its 2015 Annual Meeting of ... Because the expected date for the Annual Meeting ...
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ... low. The only negative is the housing market remaining ...
(Date:12/24/2014)... December 24, 2014 The report expects ... 19.7% by 2019. It also provides a carefully analyzed ... and challenges for the market. , Full Copy of ... report, the global market for cell expansion will keep ... It expects this growth to be driven by rapid ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Germany, May 3, 2012 , Point-of-Care ... Health program funded by Bill & Melinda Gates Foundation and ... and technologies will aid effort to create a low-cost portable ... , Development expected to be completed by ...
... for Clinical Research, Inc., a company focused on early ... record growth in the number of clinical trials in ... the number of mid-size biotech and off-shore clients, while ... driven by a strong demand for Phase I and ...
... Silence Therapeutics Plc (AIM: SLN), a leading international ... Quark Pharmaceuticals , has announced it has amended its existing ... to perform a Phase 2a clinical study to assess the ... function in patients with moderate and advanced Open-Angle Glaucoma (OAG). ...
Cached Biology Technology:QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 3QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 4QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 5Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 2Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... virus that introduces a blood pressure-lowering gene into cells and ... for four months promises to take gene therapy for the ... College of Medicine in a report released online in the ... pressure is one of the leading causes of death and ...
... in the region now known as Uganda's Kibale ... a primate still in decline. The logging practice, ... ecological balance for these monkeys, leading to behavioral ... infections. , The researchers focused on three primate ...
... grass that can grow 13 feet high, may be a ... University of Illinois at Urbana-Champaign say. , Stephen P. ... recently took that message to Dublin, Ireland, where the British ... Festival of Science Sept. 3-10. , Closer to home, two ...
Cached Biology News:Gene therapy to lower blood pressure just enough 2Affymetrix and ParAllele Launch Industry's Most Comprehensive Product Line for Targeted Genotyping 2Affymetrix and ParAllele Launch Industry's Most Comprehensive Product Line for Targeted Genotyping 3Hybrid grass may prove to be valuable fuel source 2Hybrid grass may prove to be valuable fuel source 3Hybrid grass may prove to be valuable fuel source 4
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
cystatin A (N-18)...
Human Cystatin A MAb (Clone 224705)...
Biology Products: